GGrantIndex
← Leaderboards

Hari K. Koul

Henry Ford Health System

$6,359,854
Attributed
$6,359,854
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $638.2K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,359,854 · 3
VA$0 · 2

By mechanism

R01$6,359,854 · 3
I01$0 · 2

Top collaborators

No co-investigators on record.

Most similar at Henry Ford Health System

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoPathway InteractionsCellsSignal TransductionMolecularResponseMediatingCell MotilityPhenotypeMalignant Neoplasm Of ProstateResistanceInhibitor/AntagonistGene ExpressionInvestigationTranscription FactorMissionPreventPlayProstate Cancer CellCessation Of LifeBaseAndrogensGrowthLncap

Grant awards (33)

The Role of PDEF in Prostate Cancer$0
I01 · FY2025 · VA · contact PI
Prostate Cancer Health Disparity: Role of PDEF$319,450
R01 · FY2024 · CA · contact PI
The Role of PDEF in Prostate Cancer$0
I01 · FY2024 · VA · contact PI
Prostate Cancer Health Disparity: Role of PDEF$329,537
R01 · FY2023 · CA · contact PI
The Role of PDEF in Prostate Cancer$0
I01 · FY2023 · VA · contact PI
Prostate Cancer Health Disparity: Role of PDEF$329,537
R01 · FY2022 · CA · contact PI
The Role of PDEF in Prostate Cancer$0
I01 · FY2022 · VA · contact PI
The Role of PDEF in Prostate Cancer$0
I01 · FY2021 · VA · contact PI
Prostate Cancer Health Disparity: Role of PDEF$336,263
R01 · FY2020 · CA · contact PI
Prostate Cancer Health Disparity: Role of PDEF$333,975
R01 · FY2019 · CA · contact PI
Tetrandrine for the treatment of Prostate Cancer$300,875
R01 · FY2015 · CA · contact PI
Tetrandrine for the treatment of Prostate Cancer$276,243
R01 · FY2014 · CA · contact PI
Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine$0
I01 · FY2014 · VA · contact PI
Tetrandrine for the treatment of Prostate Cancer$282,821
R01 · FY2013 · CA · contact PI
Tetrandrine for the treatment of Prostate Cancer$15,606
R01 · FY2013 · CA · contact PI
Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine$0
I01 · FY2013 · VA · contact PI
Tetrandrine for the treatment of Prostate Cancer$317,475
R01 · FY2012 · CA · contact PI
Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine$0
I01 · FY2012 · VA · contact PI
Urolithiasis: Oxalate Interactions with the Renal Cells$320,737
R01 · FY2011 · DK · contact PI
Tetrandrine for the treatment of Prostate Cancer$317,475
R01 · FY2011 · CA · contact PI
Prostate Cancer: Targeting Androgen Receptor Signaling by Tetrandrine$0
I01 · FY2011 · VA · contact PI
Urolithiasis: Oxalate Interactions with the Renal Cells$323,978
R01 · FY2010 · DK · contact PI
Urolithiasis: Oxalate Interactions with the Renal Cells$99,901
R01 · FY2010 · DK · contact PI
Urolithiasis: Oxalate Interactions with the Renal Cells$327,250
R01 · FY2009 · DK · contact PI
Urolithiasis: Oxalate Interactions with the Renal Cells$327,250
R01 · FY2008 · DK · contact PI
Urolithiasis: Oxalate Interactions With Renal Cells$289,120
R01 · FY2007 · DK · contact PI
Urolithiasis: Oxalate Interactions With Renal Cells$297,754
R01 · FY2006 · DK · contact PI
Urolithiasis: Oxalate Interactions With Renal Cells$304,920
R01 · FY2005 · DK
Urolithiasis: Oxalate Interactions With Renal Cells$304,095
R01 · FY2004 · DK
Urolithiasis: Oxalate Interactions With Renal Cells$191,015
R01 · FY2003 · DK
Urolithiasis: Oxalate Interactions With Renal Cells$123,764
R01 · FY2003 · DK
UROLITHIASIS--OXALATE INTERACTIONS WITH RENAL CELLS$146,695
R01 · FY2001 · DK
UROLITHIASIS--OXALATE INTERACTIONS WITH RENAL CELLS$144,118
R01 · FY2000 · DK